Screener
Altimmune ALT Total Operating Expenses
Total Operating Expenses at other companies
Other financials
Where this comes from
Reported directly by Altimmune in its filing.
Tagged under the XBRL concept us-gaap:OperatingExpenses.
The source filing: Altimmune’s 10-Q, filed May 13, 2026.
- Filed
- May 13, 2026, 4:13 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001326190-26-000040
| Line item | Three Months Ended / March 31, 2026 | Three Months Ended / March 31, 2025 |
|---|---|---|
| Operating expenses: | ||
| Research and development | 16,192 | 15,827 |
| General and administrative | 8,052 | 5,993 |
| Total operating expenses | 24,244 | 21,820 |
| Loss from operations | (24,244) | (21,815) |
| Other income (expense): | ||
| Interest expense | (1,068) | (1) |
| Interest income | 2,901 | 1,545 |
Item 1. Financial Statements
FAQ
- What is Altimmune's total operating expenses?
- Altimmune (ALT) reported total operating expenses of $24.24M in Q1 2026.
- How has Altimmune's total operating expenses changed year-over-year?
- Altimmune's total operating expenses increased by 11.1% year-over-year, from $21.82M to $24.24M.
- What is the long-term trend for Altimmune's total operating expenses?
- Over 4 years (2021 to 2025), Altimmune's total operating expenses has grown at a -1.7% compound annual growth rate (CAGR), from $101.32M to $94.53M.
- What does total operating expenses mean?
- The sum of all operating costs including COGS, SG&A, R&D, D&A, and other operating charges. Revenue minus total operating expenses equals operating income.
Ask your AI about Altimmune's total operating expenses.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude